UPB Upstream Bio, Inc.
$5.73▼ -0.35%
Healthcare
Other
After hours
$5.73▲ +0.00%
Sep 11, 7:30 PM ET
Volume 501.3K
Avg Volume (10D) 690.0K
Key Metrics & Fundamentals
Market Cap
$313.84M
P/E Ratio
–
Div Yield
–%
52W Range
5.65 - 33.68
% vs 50 MA
-16.24%
% vs 200 MA
-57.58%
RSI-14
34.4
MACD Histogram
-0.1100
Beta (1Y vs SPY)
1.17
Free Cash Flow
-$35.62M
Gross Rev
$773,000
Gross Profit
$773,000
EBITDA
-$42.32M
COGS
–
Operating Exp
$43.14M
Operating Income
-$42.37M
EBIT
-$42.37M
Pretax Income
-$39.70M
Net Income
-$39.70M
EPS (Diluted)
-0.72
Price & Volume History
Loading chart…
Recent News
Top Premarket Gainers
MT Newswires · Sep 8, 2026 11:15 AM
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
GlobeNewswire · Sep 8, 2026 7:30 AM
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
MT Newswires · Sep 1, 2026 11:31 AM
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
GlobeNewswire · Sep 1, 2026 11:00 AM
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 11, 2026 12:35 PM
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
GlobeNewswire · Aug 11, 2026 11:00 AM
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · Jul 14, 2026 4:00 PM
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Insider Monkey · Jun 25, 2026 12:42 PM
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
Insider Monkey · Jun 23, 2026 3:36 PM
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
GlobeNewswire · Jun 14, 2026 2:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See UPB's money flow as a full page
Social Sentiment
No Reddit posts found for UPB.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.